Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy

Table 2

Demographic and baseline data.

	A5 run-in				A10 run-in
	A10	A5	T40/A5	T80/A5	A10	T40/A10	T80/A10
Number of patients	261	671	533	426	305	306	310
Age, years mean (SD)	54.3 (10.7)	54.4 (10.2)	55.4 (10.4)	53.8 (9.8)	56.4 (10.4)	57.7 (9.4)	55.4 (9.8)
BMI, kg/m^2 mean, (SD)	28.6 (4.9)	27.1 (4.8)	27.5 (5.0)	28.4 (5.0)	30.2 (4.4)	29.6 (4.4)	30.7 (4.9)
Female, %	35.2	36.7	34.7	39.9	41.3	47.1	46.1
Race
Asian, %	20.3	69.9	60.0	49.1	0	0	0.6
Black, %	2.3	0.6	0.6	0.9	0	0	0.3
White, %	76.6	29.5	39.2	49.8	100	99.3	98.7
Other, %	0.8	0	0.2	0.2	0	0.3	0
Missing, %	0	0	0	0	0	0.3	0.3
Diabetes %	8.0	12.4	15.0	8.7	12.1	11.4	14.8
Baseline DBP, mean (SD)	96.5 (4.8)	96.4 (5.5)	96.4 (5.1)	96.7 (5.1)	95.6 (4.0)	95.5 (4.0)	95.6 (4.1)
Baseline SBP, mean (SD)	149.0 (11.8)	147.5 (12.0)	147.2 (12.3)	147.9 (11.9)	146.8 (10.2)	148.1 (9.4)	147.4 (9.4)
Duration of hypertension, years, mean (SD)	6.5 (8.0)	6.9 (7.8)	6.0 (7.4)	6.7 (7.8)	8.1 (7.1)	8.1 (7.7)	8.0 (7.5)

A5: amlodipine 5 mg; A10: amlodipine 10 mg; BMI: body mass index; DBP: diastolic blood pressure; SBP: systolic blood pressure; SD: standard deviation; T40: telmisartan 40 mg; T80: telmisartan 80 mg.